Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2016-04-20

AUTHORS

E. Palmerini, R. L. Jones, E. Marchesi, A. Paioli, M. Cesari, A. Longhi, C. Meazza, L. Coccoli, F. Fagioli, S. Asaftei, G. Grignani, A. Tamburini, S. M. Pollack, P. Picci, S. Ferrari

ABSTRACT

BackgroundFew new compounds are available for relapsed osteosarcoma. We retrospectively evaluated the activity of gemcitabine (G) plus docetaxel (D) in patients with relapsed high-grade osteosarcoma and high-grade spindle cell sarcoma of bone (HGS).MethodsPatients receiving G 900 mg/m2 d 1, 8; D 75 mg/m2 d 8, every 21 days were eligible. Primary end-point: progression-free survival (PFS) at 4 months; secondary end-point: overall survival (OS) and response rate.ResultsFifty-one patients were included, with a median age of 17 years (8–71), 26 (51 %) were pediatric patients. GD line of treatment: 2nd in 14 patients, ≥3rd in 37. 25 (49 %) patients had metastases limited to lungs, 26 (51 %) multiple sites. Histology: 40 (78 %) osteosarcoma, 11 (22 %) HGS. Eight (16 %) patients achieved surgical complete response (sCR2) after GD.Four-month PFS rate was 46 %, and significantly better for patients with ECOG 0 (ECOG 0: 54 % vs ECOG 1: 43 % vs ECOG 2: 0 %; p = 0.003), for patients undergoing metastasectomy after GD (sCR2 75 % vs no-sCR2 40 %, p = 0.02) and for osteosarcoma (osteosarcoma 56 % vs HGS 18 %; p = 0.05), with no differences according to age, line of treatment, and pattern of metastases.Forty-six cases had RECIST measurable disease: 6 (13 %) patients had a partial response (PR), 20 (43 %) had stable disease (SD) and 20 (43 %) had progressive disease (PD).The 1-year OS was 30 %: 67 % for PR, 54 % for SD and 20 % for PD (p = 0.005).ConclusionsGD is an active treatment for relapsed high-grade osteosarcoma, especially for ECOG 0 patients, and should be included in the therapeutic armamentarium of metastatic osteosarcoma. More... »

PAGES

280

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12885-016-2312-3

DOI

http://dx.doi.org/10.1186/s12885-016-2312-3

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1046613263

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/27098543


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adolescent", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Child", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Deoxycytidine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Docetaxel", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kaplan-Meier Estimate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Grading", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Recurrence, Local", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Osteosarcoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Recurrence", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sarcoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Taxoids", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "PROMETEO Laboratory/Section of Chemotherapy, Research, Innovation & Technology (RIT) Department, Istituto Ortopedico Rizzoli, Via Pupilli, 1, 40136, Bologna, Italy", 
          "id": "http://www.grid.ac/institutes/grid.419038.7", 
          "name": [
            "PROMETEO Laboratory/Chemotherapy Unit, Istituto Ortopedico Rizzoli, Bologna, Italy", 
            "PROMETEO Laboratory/Section of Chemotherapy, Research, Innovation & Technology (RIT) Department, Istituto Ortopedico Rizzoli, Via Pupilli, 1, 40136, Bologna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Palmerini", 
        "givenName": "E.", 
        "id": "sg:person.01210215667.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01210215667.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Washington/ Fred Hutchinson Cancer Research Center, Seattle, USA", 
          "id": "http://www.grid.ac/institutes/grid.430269.a", 
          "name": [
            "University of Washington/ Fred Hutchinson Cancer Research Center, Seattle, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jones", 
        "givenName": "R. L.", 
        "id": "sg:person.01110361365.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01110361365.31"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "PROMETEO Laboratory/Chemotherapy Unit, Istituto Ortopedico Rizzoli, Bologna, Italy", 
          "id": "http://www.grid.ac/institutes/grid.419038.7", 
          "name": [
            "PROMETEO Laboratory/Chemotherapy Unit, Istituto Ortopedico Rizzoli, Bologna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Marchesi", 
        "givenName": "E.", 
        "id": "sg:person.0720354404.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0720354404.13"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "PROMETEO Laboratory/Chemotherapy Unit, Istituto Ortopedico Rizzoli, Bologna, Italy", 
          "id": "http://www.grid.ac/institutes/grid.419038.7", 
          "name": [
            "PROMETEO Laboratory/Chemotherapy Unit, Istituto Ortopedico Rizzoli, Bologna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Paioli", 
        "givenName": "A.", 
        "id": "sg:person.01235471460.73", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01235471460.73"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "PROMETEO Laboratory/Chemotherapy Unit, Istituto Ortopedico Rizzoli, Bologna, Italy", 
          "id": "http://www.grid.ac/institutes/grid.419038.7", 
          "name": [
            "PROMETEO Laboratory/Chemotherapy Unit, Istituto Ortopedico Rizzoli, Bologna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cesari", 
        "givenName": "M.", 
        "id": "sg:person.0711754347.80", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0711754347.80"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "PROMETEO Laboratory/Chemotherapy Unit, Istituto Ortopedico Rizzoli, Bologna, Italy", 
          "id": "http://www.grid.ac/institutes/grid.419038.7", 
          "name": [
            "PROMETEO Laboratory/Chemotherapy Unit, Istituto Ortopedico Rizzoli, Bologna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Longhi", 
        "givenName": "A.", 
        "id": "sg:person.01167151157.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01167151157.23"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Oncoematologia Pediatrica INT, Milan, Italy", 
          "id": "http://www.grid.ac/institutes/grid.417893.0", 
          "name": [
            "Oncoematologia Pediatrica INT, Milan, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Meazza", 
        "givenName": "C.", 
        "id": "sg:person.0667021302.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0667021302.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "UO Oncoematologia Pediatrica Pisa, Pisa, Italy", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "UO Oncoematologia Pediatrica Pisa, Pisa, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Coccoli", 
        "givenName": "L.", 
        "id": "sg:person.01003463365.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01003463365.15"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Oncoematologia Pediatrica Torino, Torino, Italy", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Oncoematologia Pediatrica Torino, Torino, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fagioli", 
        "givenName": "F.", 
        "id": "sg:person.01202512663.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01202512663.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Oncoematologia Pediatrica Torino, Torino, Italy", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Oncoematologia Pediatrica Torino, Torino, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Asaftei", 
        "givenName": "S.", 
        "id": "sg:person.0744300243.09", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0744300243.09"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "IRCCS Candiolo, Torino, Italy", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "IRCCS Candiolo, Torino, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Grignani", 
        "givenName": "G.", 
        "id": "sg:person.0677322613.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0677322613.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Oncoematologia Azienda Ospedaliera Universitaria Meyer Pediatrica, Firenze, Italy", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Oncoematologia Azienda Ospedaliera Universitaria Meyer Pediatrica, Firenze, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tamburini", 
        "givenName": "A.", 
        "id": "sg:person.0760232672.04", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0760232672.04"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Washington/ Fred Hutchinson Cancer Research Center, Seattle, USA", 
          "id": "http://www.grid.ac/institutes/grid.430269.a", 
          "name": [
            "University of Washington/ Fred Hutchinson Cancer Research Center, Seattle, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pollack", 
        "givenName": "S. M.", 
        "id": "sg:person.01317174453.94", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01317174453.94"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Laboratory Research, Istituto Ortopedico Rizzoli, Bologna, Italy", 
          "id": "http://www.grid.ac/institutes/grid.419038.7", 
          "name": [
            "Laboratory Research, Istituto Ortopedico Rizzoli, Bologna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Picci", 
        "givenName": "P.", 
        "id": "sg:person.0753274552.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0753274552.44"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "PROMETEO Laboratory/Chemotherapy Unit, Istituto Ortopedico Rizzoli, Bologna, Italy", 
          "id": "http://www.grid.ac/institutes/grid.419038.7", 
          "name": [
            "PROMETEO Laboratory/Chemotherapy Unit, Istituto Ortopedico Rizzoli, Bologna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ferrari", 
        "givenName": "S.", 
        "id": "sg:person.013005321532.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013005321532.44"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2016-04-20", 
    "datePublishedReg": "2016-04-20", 
    "description": "BackgroundFew new compounds are available for relapsed osteosarcoma. We retrospectively evaluated the activity of gemcitabine (G) plus docetaxel (D) in patients with relapsed high-grade osteosarcoma and high-grade spindle cell sarcoma of bone (HGS).MethodsPatients receiving G 900\u00a0mg/m2 d 1, 8; D 75\u00a0mg/m2 d 8, every 21\u00a0days were eligible. Primary end-point: progression-free survival (PFS) at 4\u00a0months; secondary end-point: overall survival (OS) and response rate.ResultsFifty-one patients were included, with a median age of 17\u00a0years (8\u201371), 26 (51\u00a0%) were pediatric patients. GD line of treatment: 2nd in 14 patients, \u22653rd in 37. 25 (49\u00a0%) patients had metastases limited to lungs, 26 (51\u00a0%) multiple sites. Histology: 40 (78\u00a0%) osteosarcoma, 11 (22\u00a0%) HGS. Eight (16\u00a0%) patients achieved surgical complete response (sCR2) after GD.Four-month PFS rate was 46\u00a0%, and significantly better for patients with ECOG 0 (ECOG 0: 54\u00a0% vs ECOG 1: 43\u00a0% vs ECOG 2: 0\u00a0%; p\u2009=\u20090.003), for patients undergoing metastasectomy after GD (sCR2 75\u00a0% vs no-sCR2 40\u00a0%, p\u2009=\u20090.02) and for osteosarcoma (osteosarcoma 56\u00a0% vs HGS 18\u00a0%; p\u2009=\u20090.05), with no differences according to age, line of treatment, and pattern of metastases.Forty-six cases had RECIST measurable disease: 6 (13\u00a0%) patients had a partial response (PR), 20 (43\u00a0%) had stable disease (SD) and 20 (43\u00a0%) had progressive disease (PD).The 1-year OS was 30\u00a0%: 67\u00a0% for PR, 54\u00a0% for SD and 20\u00a0% for PD (p\u2009=\u20090.005).ConclusionsGD is an active treatment for relapsed high-grade osteosarcoma, especially for ECOG 0 patients, and should be included in the therapeutic armamentarium of metastatic osteosarcoma.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/s12885-016-2312-3", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1024632", 
        "issn": [
          "1471-2407"
        ], 
        "name": "BMC Cancer", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "16"
      }
    ], 
    "keywords": [
      "progression-free survival", 
      "high-grade osteosarcoma", 
      "spindle cell sarcoma", 
      "stable disease", 
      "progressive disease", 
      "partial response", 
      "overall survival", 
      "cell sarcoma", 
      "high-grade spindle cell sarcoma", 
      "surgical complete response", 
      "RECIST measurable disease", 
      "pattern of metastasis", 
      "ResultsFifty-one patients", 
      "activity of gemcitabine", 
      "line of treatment", 
      "relapsed osteosarcoma", 
      "PFS rates", 
      "ECOG 0", 
      "measurable disease", 
      "median age", 
      "pediatric patients", 
      "complete response", 
      "active treatment", 
      "metastatic osteosarcoma", 
      "therapeutic armamentarium", 
      "patients", 
      "response rate", 
      "osteosarcoma", 
      "disease", 
      "gemcitabine", 
      "sarcoma", 
      "docetaxel", 
      "metastasis", 
      "treatment", 
      "survival", 
      "age", 
      "bone", 
      "multiple sites", 
      "ConclusionsGD", 
      "MethodsPatients", 
      "metastasectomy", 
      "lung", 
      "armamentarium", 
      "months", 
      "response", 
      "Gd lines", 
      "days", 
      "rate", 
      "HGS", 
      "years", 
      "differences", 
      "new compounds", 
      "activity", 
      "cases", 
      "lines", 
      "patterns", 
      "sites", 
      "compounds", 
      "Gd"
    ], 
    "name": "Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone", 
    "pagination": "280", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1046613263"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12885-016-2312-3"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "27098543"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12885-016-2312-3", 
      "https://app.dimensions.ai/details/publication/pub.1046613263"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T16:00", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_706.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/s12885-016-2312-3"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12885-016-2312-3'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12885-016-2312-3'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12885-016-2312-3'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12885-016-2312-3'


 

This table displays all metadata directly associated to this object as RDF triples.

312 TRIPLES      20 PREDICATES      103 URIs      95 LITERALS      26 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12885-016-2312-3 schema:about N0ad1d45cf7d94e8095203ef213e029ab
2 N24fca8bc6f4e4ed3b0cdf8d368f9a024
3 N4629bbf6ecf1404faaffb1b3c46ea886
4 N64e7a4d11b7b41c49db6c1133895bfeb
5 N6f145fe6e5ec42e9848f639c7aae775f
6 N724278ac1a02400d907698120e4e4165
7 N8366b033b50c4ee7ae2837f730155db1
8 N9b95d8fc7c674b9cbf1bddd5ba2d2457
9 N9ec9cac9c6c84768993900e1081d46fe
10 Na2d9bda1770049dcbf9c384497ba2a3e
11 Nad6cd94c67b940858456bba83f3695ab
12 Naf101a3585bc4a178f60befd936aacf6
13 Nb47b7730f89d4f6984e8cc654b4d4d98
14 Nb9a77238b2044f6197bbb387f8573fc5
15 Nc693edfbd5ef415c98eaf7e8c5736edd
16 Nca61835705fb469f83eba905346d3d25
17 Ncc26ee67db904bcdb460952dd04824e8
18 Nd42fa2fd5cce47098f6fe278b0e19d83
19 Ne2087c7cf7524b74bbd009ea78c5f0c0
20 anzsrc-for:11
21 anzsrc-for:1103
22 schema:author N9531d6e3e5404e35ab7df07e570f5b29
23 schema:datePublished 2016-04-20
24 schema:datePublishedReg 2016-04-20
25 schema:description BackgroundFew new compounds are available for relapsed osteosarcoma. We retrospectively evaluated the activity of gemcitabine (G) plus docetaxel (D) in patients with relapsed high-grade osteosarcoma and high-grade spindle cell sarcoma of bone (HGS).MethodsPatients receiving G 900 mg/m2 d 1, 8; D 75 mg/m2 d 8, every 21 days were eligible. Primary end-point: progression-free survival (PFS) at 4 months; secondary end-point: overall survival (OS) and response rate.ResultsFifty-one patients were included, with a median age of 17 years (8–71), 26 (51 %) were pediatric patients. GD line of treatment: 2nd in 14 patients, ≥3rd in 37. 25 (49 %) patients had metastases limited to lungs, 26 (51 %) multiple sites. Histology: 40 (78 %) osteosarcoma, 11 (22 %) HGS. Eight (16 %) patients achieved surgical complete response (sCR2) after GD.Four-month PFS rate was 46 %, and significantly better for patients with ECOG 0 (ECOG 0: 54 % vs ECOG 1: 43 % vs ECOG 2: 0 %; p = 0.003), for patients undergoing metastasectomy after GD (sCR2 75 % vs no-sCR2 40 %, p = 0.02) and for osteosarcoma (osteosarcoma 56 % vs HGS 18 %; p = 0.05), with no differences according to age, line of treatment, and pattern of metastases.Forty-six cases had RECIST measurable disease: 6 (13 %) patients had a partial response (PR), 20 (43 %) had stable disease (SD) and 20 (43 %) had progressive disease (PD).The 1-year OS was 30 %: 67 % for PR, 54 % for SD and 20 % for PD (p = 0.005).ConclusionsGD is an active treatment for relapsed high-grade osteosarcoma, especially for ECOG 0 patients, and should be included in the therapeutic armamentarium of metastatic osteosarcoma.
26 schema:genre article
27 schema:isAccessibleForFree true
28 schema:isPartOf N2d1b31bca79c40ba9e1807026fef1f1c
29 N440e1e14b35a46b8b73db7539e30bd06
30 sg:journal.1024632
31 schema:keywords ConclusionsGD
32 ECOG 0
33 Gd
34 Gd lines
35 HGS
36 MethodsPatients
37 PFS rates
38 RECIST measurable disease
39 ResultsFifty-one patients
40 active treatment
41 activity
42 activity of gemcitabine
43 age
44 armamentarium
45 bone
46 cases
47 cell sarcoma
48 complete response
49 compounds
50 days
51 differences
52 disease
53 docetaxel
54 gemcitabine
55 high-grade osteosarcoma
56 high-grade spindle cell sarcoma
57 line of treatment
58 lines
59 lung
60 measurable disease
61 median age
62 metastasectomy
63 metastasis
64 metastatic osteosarcoma
65 months
66 multiple sites
67 new compounds
68 osteosarcoma
69 overall survival
70 partial response
71 patients
72 pattern of metastasis
73 patterns
74 pediatric patients
75 progression-free survival
76 progressive disease
77 rate
78 relapsed osteosarcoma
79 response
80 response rate
81 sarcoma
82 sites
83 spindle cell sarcoma
84 stable disease
85 surgical complete response
86 survival
87 therapeutic armamentarium
88 treatment
89 years
90 schema:name Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone
91 schema:pagination 280
92 schema:productId N411ed37fc6df436fafb9a45a71bf9e9e
93 N4b3e7feedd7e4cdaa60c619f705a0cc2
94 Nb1e7aaf53e894986ad2e9d54773de740
95 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046613263
96 https://doi.org/10.1186/s12885-016-2312-3
97 schema:sdDatePublished 2022-09-02T16:00
98 schema:sdLicense https://scigraph.springernature.com/explorer/license/
99 schema:sdPublisher N03b30ec81b214d519a3a155330d023f3
100 schema:url https://doi.org/10.1186/s12885-016-2312-3
101 sgo:license sg:explorer/license/
102 sgo:sdDataset articles
103 rdf:type schema:ScholarlyArticle
104 N03b30ec81b214d519a3a155330d023f3 schema:name Springer Nature - SN SciGraph project
105 rdf:type schema:Organization
106 N0ad1d45cf7d94e8095203ef213e029ab schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Neoplasm Recurrence, Local
108 rdf:type schema:DefinedTerm
109 N0e74b966a4b549129823878a1d7e52e2 rdf:first sg:person.01167151157.23
110 rdf:rest N62dd1e6479804c849214f8759de81df0
111 N24fca8bc6f4e4ed3b0cdf8d368f9a024 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Docetaxel
113 rdf:type schema:DefinedTerm
114 N2d1b31bca79c40ba9e1807026fef1f1c schema:issueNumber 1
115 rdf:type schema:PublicationIssue
116 N4055c96d4bd443f4b548b7f9c0921108 rdf:first sg:person.0711754347.80
117 rdf:rest N0e74b966a4b549129823878a1d7e52e2
118 N411ed37fc6df436fafb9a45a71bf9e9e schema:name pubmed_id
119 schema:value 27098543
120 rdf:type schema:PropertyValue
121 N440e1e14b35a46b8b73db7539e30bd06 schema:volumeNumber 16
122 rdf:type schema:PublicationVolume
123 N4629bbf6ecf1404faaffb1b3c46ea886 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Treatment Outcome
125 rdf:type schema:DefinedTerm
126 N46878228113e4f2cbd7f7cfe7eb749e8 rdf:first sg:person.0677322613.01
127 rdf:rest Nbad3b754796046488219eb922e9f3f78
128 N49627e46d9174c00af3e9754c23caf82 rdf:first sg:person.01003463365.15
129 rdf:rest Nf93ec5586e5d49f480a9c03901b1249a
130 N4b3e7feedd7e4cdaa60c619f705a0cc2 schema:name doi
131 schema:value 10.1186/s12885-016-2312-3
132 rdf:type schema:PropertyValue
133 N62dd1e6479804c849214f8759de81df0 rdf:first sg:person.0667021302.33
134 rdf:rest N49627e46d9174c00af3e9754c23caf82
135 N64e7a4d11b7b41c49db6c1133895bfeb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Female
137 rdf:type schema:DefinedTerm
138 N6f145fe6e5ec42e9848f639c7aae775f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Disease-Free Survival
140 rdf:type schema:DefinedTerm
141 N724278ac1a02400d907698120e4e4165 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Humans
143 rdf:type schema:DefinedTerm
144 N7966a73b74204ff0ac72feef4611d721 rdf:first sg:person.01110361365.31
145 rdf:rest N83e4d184b04145669a3a2a39b1bb79ce
146 N8366b033b50c4ee7ae2837f730155db1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Male
148 rdf:type schema:DefinedTerm
149 N83e4d184b04145669a3a2a39b1bb79ce rdf:first sg:person.0720354404.13
150 rdf:rest Nff128f6f5da6483bb5346cb9ee426523
151 N9531d6e3e5404e35ab7df07e570f5b29 rdf:first sg:person.01210215667.35
152 rdf:rest N7966a73b74204ff0ac72feef4611d721
153 N9b95d8fc7c674b9cbf1bddd5ba2d2457 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Sarcoma
155 rdf:type schema:DefinedTerm
156 N9ec9cac9c6c84768993900e1081d46fe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Deoxycytidine
158 rdf:type schema:DefinedTerm
159 Na2d9bda1770049dcbf9c384497ba2a3e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Osteosarcoma
161 rdf:type schema:DefinedTerm
162 Nad6cd94c67b940858456bba83f3695ab schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Middle Aged
164 rdf:type schema:DefinedTerm
165 Naf101a3585bc4a178f60befd936aacf6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Adolescent
167 rdf:type schema:DefinedTerm
168 Nb1e7aaf53e894986ad2e9d54773de740 schema:name dimensions_id
169 schema:value pub.1046613263
170 rdf:type schema:PropertyValue
171 Nb47b7730f89d4f6984e8cc654b4d4d98 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
172 schema:name Taxoids
173 rdf:type schema:DefinedTerm
174 Nb9a77238b2044f6197bbb387f8573fc5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Kaplan-Meier Estimate
176 rdf:type schema:DefinedTerm
177 Nb9f8af05a4eb46adb06731f0d7cfe354 rdf:first sg:person.0753274552.44
178 rdf:rest Nfea87d4a7e8c446abf99f101f4c48971
179 Nbad3b754796046488219eb922e9f3f78 rdf:first sg:person.0760232672.04
180 rdf:rest Nd783765957e74ac39e77a73b39bd6438
181 Nc693edfbd5ef415c98eaf7e8c5736edd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Recurrence
183 rdf:type schema:DefinedTerm
184 Nca61835705fb469f83eba905346d3d25 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name Neoplasm Grading
186 rdf:type schema:DefinedTerm
187 Ncc26ee67db904bcdb460952dd04824e8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
188 schema:name Child
189 rdf:type schema:DefinedTerm
190 Nd42fa2fd5cce47098f6fe278b0e19d83 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
191 schema:name Adult
192 rdf:type schema:DefinedTerm
193 Nd783765957e74ac39e77a73b39bd6438 rdf:first sg:person.01317174453.94
194 rdf:rest Nb9f8af05a4eb46adb06731f0d7cfe354
195 Ne2087c7cf7524b74bbd009ea78c5f0c0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
196 schema:name Aged
197 rdf:type schema:DefinedTerm
198 Nf6b6046083c1416991c8f9a7f9a25a17 rdf:first sg:person.0744300243.09
199 rdf:rest N46878228113e4f2cbd7f7cfe7eb749e8
200 Nf93ec5586e5d49f480a9c03901b1249a rdf:first sg:person.01202512663.01
201 rdf:rest Nf6b6046083c1416991c8f9a7f9a25a17
202 Nfea87d4a7e8c446abf99f101f4c48971 rdf:first sg:person.013005321532.44
203 rdf:rest rdf:nil
204 Nff128f6f5da6483bb5346cb9ee426523 rdf:first sg:person.01235471460.73
205 rdf:rest N4055c96d4bd443f4b548b7f9c0921108
206 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
207 schema:name Medical and Health Sciences
208 rdf:type schema:DefinedTerm
209 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
210 schema:name Clinical Sciences
211 rdf:type schema:DefinedTerm
212 sg:journal.1024632 schema:issn 1471-2407
213 schema:name BMC Cancer
214 schema:publisher Springer Nature
215 rdf:type schema:Periodical
216 sg:person.01003463365.15 schema:affiliation grid-institutes:None
217 schema:familyName Coccoli
218 schema:givenName L.
219 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01003463365.15
220 rdf:type schema:Person
221 sg:person.01110361365.31 schema:affiliation grid-institutes:grid.430269.a
222 schema:familyName Jones
223 schema:givenName R. L.
224 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01110361365.31
225 rdf:type schema:Person
226 sg:person.01167151157.23 schema:affiliation grid-institutes:grid.419038.7
227 schema:familyName Longhi
228 schema:givenName A.
229 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01167151157.23
230 rdf:type schema:Person
231 sg:person.01202512663.01 schema:affiliation grid-institutes:None
232 schema:familyName Fagioli
233 schema:givenName F.
234 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01202512663.01
235 rdf:type schema:Person
236 sg:person.01210215667.35 schema:affiliation grid-institutes:grid.419038.7
237 schema:familyName Palmerini
238 schema:givenName E.
239 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01210215667.35
240 rdf:type schema:Person
241 sg:person.01235471460.73 schema:affiliation grid-institutes:grid.419038.7
242 schema:familyName Paioli
243 schema:givenName A.
244 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01235471460.73
245 rdf:type schema:Person
246 sg:person.013005321532.44 schema:affiliation grid-institutes:grid.419038.7
247 schema:familyName Ferrari
248 schema:givenName S.
249 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013005321532.44
250 rdf:type schema:Person
251 sg:person.01317174453.94 schema:affiliation grid-institutes:grid.430269.a
252 schema:familyName Pollack
253 schema:givenName S. M.
254 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01317174453.94
255 rdf:type schema:Person
256 sg:person.0667021302.33 schema:affiliation grid-institutes:grid.417893.0
257 schema:familyName Meazza
258 schema:givenName C.
259 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0667021302.33
260 rdf:type schema:Person
261 sg:person.0677322613.01 schema:affiliation grid-institutes:None
262 schema:familyName Grignani
263 schema:givenName G.
264 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0677322613.01
265 rdf:type schema:Person
266 sg:person.0711754347.80 schema:affiliation grid-institutes:grid.419038.7
267 schema:familyName Cesari
268 schema:givenName M.
269 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0711754347.80
270 rdf:type schema:Person
271 sg:person.0720354404.13 schema:affiliation grid-institutes:grid.419038.7
272 schema:familyName Marchesi
273 schema:givenName E.
274 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0720354404.13
275 rdf:type schema:Person
276 sg:person.0744300243.09 schema:affiliation grid-institutes:None
277 schema:familyName Asaftei
278 schema:givenName S.
279 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0744300243.09
280 rdf:type schema:Person
281 sg:person.0753274552.44 schema:affiliation grid-institutes:grid.419038.7
282 schema:familyName Picci
283 schema:givenName P.
284 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0753274552.44
285 rdf:type schema:Person
286 sg:person.0760232672.04 schema:affiliation grid-institutes:None
287 schema:familyName Tamburini
288 schema:givenName A.
289 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0760232672.04
290 rdf:type schema:Person
291 grid-institutes:None schema:alternateName IRCCS Candiolo, Torino, Italy
292 Oncoematologia Azienda Ospedaliera Universitaria Meyer Pediatrica, Firenze, Italy
293 Oncoematologia Pediatrica Torino, Torino, Italy
294 UO Oncoematologia Pediatrica Pisa, Pisa, Italy
295 schema:name IRCCS Candiolo, Torino, Italy
296 Oncoematologia Azienda Ospedaliera Universitaria Meyer Pediatrica, Firenze, Italy
297 Oncoematologia Pediatrica Torino, Torino, Italy
298 UO Oncoematologia Pediatrica Pisa, Pisa, Italy
299 rdf:type schema:Organization
300 grid-institutes:grid.417893.0 schema:alternateName Oncoematologia Pediatrica INT, Milan, Italy
301 schema:name Oncoematologia Pediatrica INT, Milan, Italy
302 rdf:type schema:Organization
303 grid-institutes:grid.419038.7 schema:alternateName Laboratory Research, Istituto Ortopedico Rizzoli, Bologna, Italy
304 PROMETEO Laboratory/Chemotherapy Unit, Istituto Ortopedico Rizzoli, Bologna, Italy
305 PROMETEO Laboratory/Section of Chemotherapy, Research, Innovation & Technology (RIT) Department, Istituto Ortopedico Rizzoli, Via Pupilli, 1, 40136, Bologna, Italy
306 schema:name Laboratory Research, Istituto Ortopedico Rizzoli, Bologna, Italy
307 PROMETEO Laboratory/Chemotherapy Unit, Istituto Ortopedico Rizzoli, Bologna, Italy
308 PROMETEO Laboratory/Section of Chemotherapy, Research, Innovation & Technology (RIT) Department, Istituto Ortopedico Rizzoli, Via Pupilli, 1, 40136, Bologna, Italy
309 rdf:type schema:Organization
310 grid-institutes:grid.430269.a schema:alternateName University of Washington/ Fred Hutchinson Cancer Research Center, Seattle, USA
311 schema:name University of Washington/ Fred Hutchinson Cancer Research Center, Seattle, USA
312 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...